Miragen Therapeutics [NASDAQ: MGEN] gained 13.24% on the last trading session, reaching $1.24 price per share at the time. The company report on July 23, 2020 that Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma.
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemia/lymphoma (ATLL).
“This is an important milestone in the development of cobomarsen. We believe the FDA’s decision to grant cobomarsen orphan drug designation underscores the need for new treatments for T-cell lymphomas such as ATLL and CTCL,” stated miRagen President and Chief Executive Officer William S. Marshall, Ph.D. “In addition to the promising results we’ve observed for the potential treatment of patients with ATLL and CTCL, we believe that cobomarsen has the potential to be a broad-based therapy for the treatment of cancer patients with elevated levels of miR-155.”.
Miragen Therapeutics represents 53.08 million in outstanding shares, while the company has a total market value of $58.09 million with the latest information. MGEN stock price has been found in the range of $1.21 to $1.61.
If compared to the average trading volume of 2.15M shares, MGEN reached a trading volume of 44260418 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Miragen Therapeutics [MGEN]:
Robert W. Baird have made an estimate for Miragen Therapeutics shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2019. The new note on the price target was released on January 04, 2019, representing the official price target for Miragen Therapeutics stock. Previously, the target price had yet another raise to $18.50, while B. Riley FBR analysts kept a Buy rating on MGEN stock.
The Average True Range (ATR) for Miragen Therapeutics is set at 0.17, with the Price to Sales ratio for MGEN stock in the period of the last 12 months amounting to 11.86. The Price to Book ratio for the last quarter was 2.10, with the Price to Cash per share for the same quarter was set at 0.77.
Trading performance analysis for MGEN stock
Miragen Therapeutics [MGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.98. With this latest performance, MGEN shares gained by 7.83% in over the last four-week period, additionally plugging by 27.84% over the last 6 months – not to mention a drop of -39.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MGEN stock in for the last two-week period is set at 61.10, with the RSI for the last a single of trading hit 66.57, and the three-weeks RSI is set at 59.45 for Miragen Therapeutics [MGEN]. The present Moving Average for the last 50 days of trading for this stock 0.9718, while it was recorded at 1.0990 for the last single week of trading, and 0.7628 for the last 200 days.
Miragen Therapeutics [MGEN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Miragen Therapeutics [MGEN] shares currently have an operating margin of -941.02. Miragen Therapeutics’s Net Margin is presently recorded at -938.65.
Return on Total Capital for MGEN is now -97.97, given the latest momentum, and Return on Invested Capital for the company is -105.43. Return on Equity for this stock declined to -124.81, with Return on Assets sitting at -86.87. When it comes to the capital structure of this company, Miragen Therapeutics [MGEN] has a Total Debt to Total Equity ratio set at 52.71. Additionally, MGEN Total Debt to Total Capital is recorded at 34.52, with Total Debt to Total Assets ending up at 27.44. Long-Term Debt to Equity for the company is recorded at 27.47, with the Long-Term Debt to Total Capital now at 17.99.
Reflecting on the efficiency of the workforce at the company, Miragen Therapeutics [MGEN] managed to generate an average of -$910,283 per employee. Receivables Turnover for the company is 67.59 with a Total Asset Turnover recorded at a value of 0.09.Miragen Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.
Miragen Therapeutics [MGEN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Miragen Therapeutics posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MGEN.
An analysis of insider ownership at Miragen Therapeutics [MGEN]
There are presently around $14 million, or 21.50% of MGEN stock, in the hands of institutional investors. The top three institutional holders of MGEN stocks are: FMR LLC with ownership of 3,888,656, which is approximately 34.618% of the company’s market cap and around 0.10% of the total institutional ownership; ATLAS VENTURE ADVISORS, INC., holding 3,142,580 shares of the stock with an approximate value of $3.9 million in MGEN stocks shares; and VANGUARD GROUP INC, currently with $2.0 million in MGEN stock with ownership of nearly 147.296% of the company’s market capitalization.
Positions in Miragen Therapeutics stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 21 institutional holders increased their position in Miragen Therapeutics [NASDAQ:MGEN] by around 3,145,248 shares. Additionally, 8 investors decreased positions by around 597,010 shares, while 8 investors held positions by with 7,692,531 shares. The mentioned changes placed institutional holdings at 11,434,789 shares, according to the latest SEC report filing. MGEN stock had 15 new institutional investments in for a total of 985,726 shares, while 5 institutional investors sold positions of 414,974 shares during the same period.